Mr. Cola was most recently President of Shire plc's Specialty Pharmaceuticals business, where he oversaw all aspects of this $2.5 billion enterprise. He joined Shire in 2005 as Executive Vice President of Global Therapeutic Business Units and Portfolio Management. Previously he was with Safeguard Scientifics, where he served as President of the Life Sciences Group. While at Safeguard Scientifics, Mr. Cola served as Chairman and CEO of Clarient, a cancer diagnostics company acquired by GE Healthcare, and as Chairman of Laureate Pharma, a full-service contract manufacturing organization serving research-based biologics companies. Prior to Safeguard Scientifics, Mr. Cola held senior positions in product development and commercialization at AstraMerck, a top 20 U.S. pharmaceutical company, and at AstraZeneca.
Mr. Cola received a BA in biology and physics from Ursinus College and an MS in biomedical science from Drexel University. He serves on the Board of Directors of Vanda Pharmaceuticals, NuPathe and Pennsylvania BIO, the statewide association representing the bioscience community. He also serves as Chairman of the Board of Governors of the Boys & Girls Clubs of Philadelphia.
"It is an honor to lead Medgenics at this exciting time in the company's development," stated Mr. Cola. "Our company is built upon a potential breakthrough technology in gene therapy and protein production that represents a safe and reversible approach that also shows promise to individually dose the production of therapeutic proteins. I am particularly pleased to have Garry and John joining me. Having worked with each of them in the past, I know they have the skills and leadership to advance our gene therapy and protein therapeutics technology and build a successful company. Following a thorough review of our assets and target markets, we look forward to rolling out our team's strategy and advancing Medgenics into what promises to be an exciting future."
Sol continues to build the team..
Medgenics, Inc. (nyse mkt:MDGN and AIM)(nyse mkt:MEDG), developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces the appointment of a new executive leadership team with the goal of accelerating the development of the company's gene therapy platform and maximizing the value of the company's technology assets. The new executives are Michael Cola, President and Chief Executive Officer, John Leaman, M.D., Chief Financial Officer, and Garry Neil, M.D., Global Head of Research and Development. In addition, on September 13, 2013, Mr. Cola joined the Medgenics' Board of Directors.
Google article title if interested
"The building is funded in part by a $20 million donation from Philip Milstein, CC ’71, and Cheryl Milstein, BC ’82, and a $50 million donation from Roy Vagelos, P&S ’54, and Diana Vagelos, BC ’55. It will house new classrooms, study and lab space, and a high-tech medical procedure simulation center."
Agreed, and knowing these CHF patients, (father was one) the less invasive surgery is a BLESSING, and potentially the only way some of these patients could have access to this type of technology. My father never could have handled the VAD surgery, but this, he might have been able to make it through.
"His new projects–the heart medicine, the asthma drug–might just be the kind that save thousands of lives or become household names."
“Everything that we’ve been doing for 25 years, it interconnects,” says Yancopoulos. “It’s not like we changed direction in the middle, or we did a new trick. It’s all building on the foundation of those early ideas, and we’re just taking them to the next level.”
Lets try this again,
Google article title/subject if interested
"How an entrepreneur, a research genius and an industry legend built this century’s most inventive new drug company. Together they just might change medicine"
"According to a Forbes analysis of 220 drugs approved over the past decade for publicly traded companies, the companies that invented three or more medicines spent an average $4.3 billion in R&D per drug. The big boys spend still more: $5.5 billion for Merck, $7.8 billion for Pfizer and $10 billion for Sanofi, Regeneron’s partner in many of its projects. Regeneron’s cost per drug? Only $736 million. “He’s been successful beyond anything I could imagine,” says Fred Alt, the Harvard Medical School geneticist who first told Schleifer about Yancopoulos."
"Accordingly, Schleifer is approaching billionaire status. He’s worth $800 million, largely in Regeneron stock, according to Forbes estimates. Meanwhile, Yancopoulos has made more money than almost any research biologist in history. Last year, he received a $82 million pay package, also mostly stock, which bettered every chief executive in America except Oracle’s Larry Ellison. His estimated total net worth: $400 million."
"On September 16, 2013, AstraZeneca (NYSE: AZN) filed a New Drug Application (“NDA”) with the United States Food and Drug Administration (“FDA”) for naloxegol. Under the terms of the License Agreement, dated September 20, 2009, as amended, between AstraZeneca and Nektar Therapeutics (Nasdaq: NKTR)), AstraZeneca is obligated to pay Nektar a $70 million milestone payment within 5 business days of acceptance of the NDA by the FDA. The FDA typically makes its acceptance determinations regarding NDAs within 60 days after filing, although the outcome and exact timing of such acceptance determination remains subject to the discretion of the FDA."
Google subject/article title if interested.
If your interested in a more formative/speculative play, check out MDGN. Picked up an impressive jockey a while back, and seems to be catching a bid. Again, I'm in at much lower prices, but if they succeed at what they are working on, the ride north will be a long one. :-) Check out todays volume.
P.S. HALO seems to be getting some upward momentum, along with NKTR, and CLDX. Im in at much lower prices, but feels like the wind is building in their sales.
Still holding my THOR, I think they have a very strong management team, as well as product. Looking to add more to core and get back some trading shares, just pondering timing and or event that pushes me to pull he trigger.
Congrats on the SSH, its been cooperating with its volatility for training.
Ah, but the NEW news is they are committing people, and dollars to DEVELOP, not just talk about it.